EXECUTIVE SUMMARY

1

Direct Benefit to Patient

Fast, risk free diagnosis without any invasive procedure for patients advised an invasive
biopsy.

2

What

Non-Invasive Diagnostic biopsy to substitute invasive tissue extraction.

3

For Whom

Symptomatic individuals
who have been advised a biopsy to check for malignancy.

Patients where an invasive
biopsy has been inconclusive or inconsistent with clinical
observations.

Suspected metastatic relapse to rule out new primary.

4

Why

Invasive biopsies are risky, inconvenient, painful and must be performed in a clinical
setting. Trublood sample can be collected from patient’s home or office.

5

How

Circulating Tumor Cells and Nucleic Acid are isolated from patient’s blood samples and
extensively analysed for diagnosis, prognosis and theranostics.

6

Sample Type

17 / 25 ml peripheral blood (5-6 hours fasting) as per protocol depending upon extent of
test.

7

Turn Around Time

Report will be available within 5-10 days depending upon test.

ADVANTAGE OF TRUBLOOD® OVER TISSUE BIOPSY

Usual Tissue Biopsy / FNAC Trublood
Invasive, needs tissue and is ultimately expensive Totally non invasive and is ultimately less expensive
Can be performed only in Hospital / with Anesthesia No need for Hospitalization / Anesthesia
Usually painful, may need stitches and leave scars No Pain, No Stitches, No Scars
Serious risk of tumor cell ‘Seeding’ No Risk
Can be very risky for organs like Lung, Liver, Pancreas No risk of injury to any organ / bleeding
May be misleading as it is site / time dependent Provides ‘Real time’ data and covers all active sites
Serial / sequential biopsies are impossible Can be performed as often as necessary
Not viable if primary tumor is not easily visualized Viable even if primary / metastasis are undetectable

ILLUSTRATIVES


SCHEDULE OF ANALYTES

Cancer Type Analysis Type
ICC cfDNA*/ RNA FISH*
CNS (Brain)
Head and Neck
Thyroid
Breast
Lung
Liver
Gallbladder
Pancreatic
Uterine
Ovarian
Cervix
Esophageal
Gastric
Colorectal
Prostate
Kidney
Bladder
Sarcoma
Melanoma

* Optional at extra cost.

ADVANTAGES OF TRUBLOOD

  • Blood based, Non-invasive
  • Safe
  • Accurate
  • Easy on the Patient
  • Reasonable Charges
  • Available for all solid organs

WHO WILL BENEFIT

Symptomatic individuals who have
been advised a biopsy to check for malignancy.

Patients where an invasive biopsy
has been inconclusive or inconsistent with clinical observations.

Suspected metastatic relapse to
rule out new primary.

Trublood®

The anxiety, pain, risks and costs associated with invasive biopsies for cancer diagnosis are
substantial. A reliable, safe and convenient test to establish diagnosis in suspected cases
of cancer has not been available.

Trublood® has been clinically validated on more than 40,000 samples from patients and healthy
individuals to whom we are ever grateful. Trublood® is a revolutionary non-invasive, safe
and accurate blood test that can substitute invasive biopsies in most suspected cases of
solid organ cancers. With a simple 20-25 ml of blood draw, the Trublood® analysis involves
extremely sensitive, sophisticated and careful isolation and analysis of ‘live’ tumor cells
and Nucleic Acid Fragments (DNA / RNA) from the patient’s blood.

A comprehensive report is provided with unprecedented level of information which was hitherto
thought impossible. Trublood® can be repeated as often as necessary, even during treatment
or thereafter for real time characterization and personalization of treatment.

Trublood® is a result of several years of research put in by more than 150 of our scientists
and clinicians working as a team using the world’s latest equipment and software.

Trublood® is a new paradigm in cancer diagnosis and management.

SPECIMEN REQUIREMENTS

BASIC DIAGNOSTICS

Thus, total 4 tubes containing 17 ml
whole blood.

BASIC DIAGNOSTICS + cfDNA + RNA + FISH + PHARMACOGENETICS

Thus, total 5 tubes containing 25 ml
whole blood.

Note :

    • Sequence of draw should not be altered.
    • Blood should be drawn only and only as per above method.
    • Blood drawn should be performed only by qualified phlebotomist under medical
      supervision.
    • Ship 4 °C in the container provided by DCG.

OTHER PRECAUTIONS PRIOR TO COLLECTION OF BLOOD SAMPLE

  • The patient must not have received any form of cancer therapy (radiation / chemotherapy
    / surgery / endocrine etc.) at least 30 days prior to collection of sample.
  • The patient must not have received oral or IV corticosteroids at least 14 days prior to
    collection of sample.
  • Patient has no current febrile or any other acute inflammatory illness.
  • Patient does not have acute exacerbation or flareup of an inflammatory condition
    requiring escalation in medical therapy at least 5 days prior to collection of sample.
  • Patient has not received blood transfusion / PET-CT / CTscan at least 5 days prior to
    collection of sample.
  • Patient is not positive for HIV / HBV / HCV.

7 EASY STEPS TO TRUBLOOD®

1

Patient Enquiry

2

Response

Our representative will contact you in 6 Hrs

3

Help to choose the appropriate test

You can ask our representative to help in selection of the most
appropriate test

4

Payment

5

Sample Transportation

We can assist you with the logistics
(Please see our specimen
requirement)

6

Sample Processing

7

Report Generation and Dispatch

VALIDATION

Trublood® non-invasive diagnostic biopsy for solid organ cancers has been developed by
Datar Cancer Genetics based on the findings of two clinical trials registered with the CTRI
(Registration No. CTRI/2019/01/017219 and CTRI/2019/03/017918).

Trublood has been extensively validated with data from more than 22,000 samples from
asymptomatic individual donors who underwent currently used screening tests such as LDCT,
Mammography, PAP Smear, Serum CA Markers and clinical examinations, as well as more than
18,000 samples from cancer patients / patients with benign conditions totalling more than
40,000 evaluable samples till December, 2019.

EVALUTED SAMPLES (PATIENTS)

Cancer Type Patients
Breast 3967
Head and Neck 3552
Lung 1378
Colorectal 1341
Prostate 1196
Cervix 930
Ovary 855
Esophagus 507
Sarcoma 440
Stomach 392
Uterus + Endometrium 365
Pancreas 385
Liver 381
CNS 349
Kidney 342
Bladder 249
Bone 220
Gallbladder 196
Thyroid 175
Testes 135
Skin 115
Melanoma 86
Penis 72
Neuroendocrine 51
Others 154
Total 17,833

SUMMARY

Particulars Samples
All Cancers 17,833
Benign Conditions 488
Asymptomatic Individuals 22,030
Total 40,351

BASIS

  • Tumors release thousands of cells into the circulation, where circulating tumor cells
    (CTCs) survive for about 1–2.5 hours.
  • In order to detach from the primary tumor and disseminate into the blood, cells must
    undergo a cellular process known as Epithelial-Mesenchymal Transition (EMT).
  • EMT enhances migratory capabilities of tumor cells, which allows cells to penetrate into
    the vasculature and circulate as single or clusters of circulating tumor cells (CTCs).
  • CTCs extravasate having undergone the reverse process known as Mesenchymal to Epithelial
    Transition (MET) and colonize at distant organs.
  • Circulating Tumor Cells (CTCs) are defined as EpCAM (+), PanCK (+), CD45 (-) cells.
    Circulating Tumor Associated Cells (C-TACs) are EpCAM(+), PanCK(+), CD45(+/-) cells of
    tumorigenic origin, in peripheral blood.
  • Non-tumorigenic cells in peripheral blood have functional apoptotic mechanism, but CTC
    and C-TACs are resistant to apoptosis.
  • An epigenetically active stabilizing process can eliminate normal cells and confer
    survival privilege on apoptosis – resistant C-TACs, CTC and C-TACs.
  • Sufficient C-TACs can be enriched and harvested for Immunocytochemistry (ICC) profiling
    with markers used in immunohistochemistry (IHC) which aid in determination of
    histopathological subtypes of tumor tissue.
  • Antibody clones used in the trublood® assay for analysis of tumor antigens/markers
    are internationally approved for IVD use.

DOWNLOAD BROCHURE

PDF will be emailed

 

I have read and understood the terms of use and the privacy policy and I agree.

FREQUENTLY ASKED QUESTIONS

Can Trublood® detect all cancers?

Trublood® detects presence of carcinoma i.e. epithelial malignancies, melanoma as well as
certain subtypes of sarcoma. It does not detect haematolymphoid malignancies. Carcinomas
are the most common malignancy in adults.

Can Trublood® differentiate between squamous cell carcinoma and
adenocarcinoma?

Can Trublood® always provide specific histopathological subtype?
Can it identify rare HPE subtype?

Can Trublood® give us the histological grade of the tumor?

What is the principle used in Trublood®?

How is Trublood® different from a Circulating Tumor Cell (CTC)
test?

Can I use Trublood® for longitudinal CTC enumeration?

Can you find CTCs in blood when there is Carcinoma in situ? / Can
Trublood® identify carcinoma in situ?

Can you find CTCs in early stage cancer?

How does it give guidance for therapy?

How does it differ from other cancer screening methods e.g.
CA125, CA19-9, etc.?

Can Trublood® be offered to a person with non-specific cancer
symptoms such as cachexia without clinical suspicion of a particular organ involvement?

How is the sample collected? Is there any special procedure for
collection?

How is the sample transported?

What is the next step if Trublood® gives positive result?

Do I need to confirm the presence of malignancy with an invasive
biopsy when Trublood® results are positive?

Do you have any comparative data?

How is the performance of Trublood®? What is the validation you
have for this test?

Is it being used by clinicians anywhere?

What if the test is inconclusive?

Can Trublood® be availed for childhood malignancies?

What advantage does Trublood® offer over tissue biopsy?

What are the limitations of Trublood®?

Can Trublood® give theragnostic information similar to that
obtained by tissue biopsy?

Will doctor treat me based on Trublood® result?

Can Trublood® be used in haematological malignancies?

CONTACT US

I have read and understood the terms of use and the privacy policy and I agree.